Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

Oncotarget

Volumn 7, Issue 41, 2016, Pages 67142-67149

  Gardini, Andrea Casadei ^a   Scarpi, Emanuela ^a   Faloppi, Luca ^b,c   Scartozzi, Mario ^c   Silvestris, Nicola ^d   Santini, Daniele ^e   de Stefano, Giorgio ^f   Marisi, Giorgia ^a   Negri, Francesca V ^g   Foschi, Francesco Giuseppe ^h   Valgiusti, Martina ^a   Ercolani, Giorgio ^i,j   Frassineti, Giovanni Luca ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b Ospedale Generale Provinciale di Macerata   (Italy)

^c DEPARTMENT OF RADIOLOGY   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^g UNIVERSITY HOSPITAL OF PARMA   (Italy)

^h Faenza Hospital   (Italy)

ⁱ MORGAGNI PIERANTONI HOSPITAL   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Biomarker; Hepatocellular carcinoma; Inflammation; Neutrophil to lymphocyte ratio; Systemic immune inflammation index

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOMODULATION; INFLAMMATION; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SYSTEMIC IMMUNE INFLAMMATION INDEX; THROMBOCYTE COUNT; AGED; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84993997499     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11565     Document Type: Article

References (27)

1. Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E, et al. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opin Pharmacother. 2015; 16:2719-2725. doi: 10.1517/14656566.2015.1102887.
2. Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E, Faloppi L, Scartozzi M, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba G, et al. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget. 2016; 7:15243-15251. doi: 10.18632/oncotarget.7444.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10:25-34. doi: 10.1016/S1470-2045(08)70285-7.
4. Coffelt SB and de Visser KE. Cancer: Inflammation lights the way to metastasis. Nature. 2014; 507:48-49. doi: 10.1038/nature13062.
5. Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Giuseppe Foschi F, Iavarone M, Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Corte C, Maria Neri L, Tamberi S, et al. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016; 7:27988-27999. doi: 10.18632/oncotarget.8569.
6. Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A, Andrikou K, Del Prete M, Cascinu S, Scartozzi M. Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int. 2016; 2016:7196280. doi: 10.1155/2016/7196280.
7. Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P. Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC Cancer. 2016; 16:429. doi: 10.1186/s12885-016-2463-2.
8. Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P, Ferri L. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest. 2013. doi: 10.1172/JCI67484.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867. doi:10.1038/nature01322.
10. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012; 12:264-269. doi: 10.1016/j.clbc.2012.04.004.
11. Faloppi L, Scartozzi M, Bianconi M, Svegliati Baroni G, Toniutto P, Giampieri R, Del Prete M, De Minicis S, Bitetto D, Loretelli C, D'Anzeo M, Benedetti A, Cascinu S. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer. 2014;14:110. doi: 10.1186/1471-2407-14-110.
12. Faloppi L, Scartozzi M, Maccaroni E, Di Pietro Paolo M, Berardi R, Del Prete M, Cascinu S. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev. 2011; 37:169-177. doi: 10.1016/j.ctrv.2010.08.001.
13. Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandala M, Simeone E, Valpione S, Altomonte M, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016; 27:732-738. doi: 10.1093/annonc/mdw016.
14. Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, Cappellini GC, De Galitiis F, Marchetti P, Amato G, Lazzeri A, Pala L, Cocorocchio E, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015; 112:1904-1910. doi: 10.1038/bjc.2015.180.
15. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014; 20:6212-6222. doi: 10.1158/1078-0432.CCR-14-0442.
16. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95-100. doi: 10.1634/theoncologist.2008-0185.
17. Kobayashi N, Usui S, Kikuchi S, Goto Y, Sakai M, Onizuka M, Sato Y. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer. 2012; 75:223-227. doi: 10.1016/j.lungcan.2011.06.009.
18. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011; 20:576-590. doi: 10.1016/j.ccr.2011.09.009.
19. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18: 2290-2300. doi: 10.1158/1078-0432.CCR-11-2175.
20. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390. doi: 10.1056/NEJMoa0708857.
21. Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology. 2013; 2:e26468. doi: 10.4161/onci.26468.
22. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29:1093-1102. doi: 10.1038/onc.2009.416.
23. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12:681-700. doi: 10.1038/nrgastro.2015.173.
24. Rossi L, Santoni M, Crabb SJ, Scarpi E, Burattini L, Chau C, Bianchi E, Savini A, Burgio SL, Conti A, Conteduca V, Cascinu S, De Giorgi U. High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol. 2015; 22:1377-1384. doi: 10.1245/s10434-014-4097-4.
25. Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, Toniutto P, Fava G, De Minicis S, Mandolesi A, Bianconi M, Giampieri R, Granito A, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014; 135:1247-1256. doi: 10.1002/ijc.28772.
26. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013; 24:130-137. doi: 10.1016/j.ccr.2013.05.008.
27. Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer. 2013; 2:93-107. doi: 10.1159/000343845.